id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-260779-riw5xs3j	van Griensven, Johan	The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field	2016-01-01		.txt	text/plain	3825	199	46	The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone, and Liberia, was prioritized by the World Health Organization in September 2014. The World Health Organization (WHO) guidelines recommend both convalescent whole blood (CWB) and CP for use against Ebola virus disease (EVD) [12] . Blood transfusion is routinely done in all 3 high-transmission countries involved in the current EVD outbreak; however, plasma has numerous advantages in these settings. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. Clinical trial to evaluate the efficacy and safety of convalescent plasma for Ebola treatment (EVD001). Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease	./cache/cord-260779-riw5xs3j.txt	./txt/cord-260779-riw5xs3j.txt